NPM1 and chronic myelomonocytic leukemia: The study by Patel et al. [6] reported unfavorable overall outcomes in their cohort of NPM1-mutated myeloid neoplasms (including CMML and MDS), with the majority of patients undergoing initial HMA therapy.